622372-89-8

Upstream product

• 609-65-4 o-chlorobenzoyl chloride 
• 109-04-6 2-bromo-pyridine 
• 6392-26-3 (2-chlorophenyl)(morpholino)methanone 
• 622372-79-6 (2-bromo-pyridin-3-yl)-(2-chlorophenyl)-methanol 

Downstream Products

• 1035920-11-6 C₁₉H₁₃ClN₂O₂ 
• 622370-35-8 [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)-methanone 

Relevant academic research and scientific papers

PROCESS DEVELOPMENT OF A PYRIDINE-CONTAINING NK-1 RECEPTOR ANTAGONIST

The disclosure provides process developments and novel routes for the preparation of the NK-1 receptor antagonist, Compound (I) and intermediates in those routes.

NOVEL CRYSTALLINE FORMS OF {2-[1-(3,5-BIS-TRIFLUOROMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-CHLOROPHENYL)-METHANONE

The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]- pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof. X-16289

TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C1-C3 alkane-diyl; R1 is phenyl, which is optionally substituted with one to three substitutents indpendently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R4 is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH)